|Expands Health Food Business Leveraging Advanced Japanese Technology|
HONG KONG, Aug 15, 2017 - (ACN Newswire) - PuraPharm Corporation Limited ("PuraPharm" or the "Group", HKEX: 1498), a leading Hong Kong-based Chinese medicine company, has announced that it entered into share purchase agreements through its Japanese subsidiary to acquire SODX Co., Ltd. ("SODX"), a Japan-based company that principally engages in the manufacturing and sale of health food in Japan, at a total consideration of JPY244.0 million (equivalent to approximately HK$17.1 million). Upon completion of the acquisition, SODX will become an indirect wholly-owned subsidiary of the Group.
Based in Izumi City, Osaka, Japan, SODX is certified by the Japanese Institute for Health Food Standards as Good Manufacturing Practice ("GMP") health products manufacturer that produces its own branded products as well as manufactures health products and packaging specified by its customers. It specialises in producing dietary supplement products using fermented soybeans and antioxidant products. SODX is also recognised for developing patented products, including health food product that contains thrombolytic enzyme. SODX has received widespread recognition and support from the health food products industry due to its high-quality products, capability of making various dosage forms and advanced equipment for product packaging.
The acquisition will provide PuraPharm with a cost- and time-effective means of developing its health food business, leveraging SODX's expertise and resources. SODX's factory will serve as a pilot factory to transfer the latest technological know-how from Japan to further improve the quality and production efficiency of PuraPharm's Chinese healthcare products. The pilot factory will also act as the Group's new product development centre for business expansion.
Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm, said, "I am delighted to announce the acquisition of SODX, which gives us immediate access to state-of-the-art technology used for Japanese health products. This will not only complement our existing healthcare product portfolio, but will also further improve our product quality; enabling us to raise our competitiveness in the market."
About PuraPharm Corporation Limited
PuraPharm is a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of CCMG products which the Group markets under its "Nong's" brand. PuraPharm is the largest supplier of CCMG products in Hong Kong with a market share of 70% in terms of prescription revenue for the Hong Kong CCMG product market in 2014, according to the Euromonitor Report. The Group also sells a broad range of general Chinese healthcare products, such as PuraGold and Oncozac, which are essentially Chinese herbal supplements, on an OTC basis, targeting end-consumers. PuraPharm operates the largest Chinese medicine clinic chain in Hong Kong. PuraPharm's shares have been listed on the Main Board of the Stock Exchange of Hong Kong Limited since 8 July 2015 under the stock code 1498.
Strategic Financial Relations Limited
Heidi So +852 2864 4826 firstname.lastname@example.org
Fanny Yuen +852 2864 4853 email@example.com
Jessica Siu +852 2114 2820 firstname.lastname@example.org
Topic: Press release summary
Source: PuraPharm Corporation Limited
Sectors: Food & Beverage, Daily News, Healthcare & Pharm
From the Asia Corporate News Network
Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.